Results 21 to 30 of about 1,481 (180)

ESKALE study, a French real-world study of esketamine nasal spray for patients with treatment-resistant depression [PDF]

European Psychiatry, 2022
Introduction Esketamine nasal spray has been developed to treat adults with treatment resistant depression. On Dec.2019, EMA granted a market access approval in this indication. Objectives ESKALE is a descriptive study of treatment resistant depression
S. Ludovic, M.A. Codet, M. Rotharmel, P. De Maricourt, J. Boursicot, E. Gaudre Wattinne   +5 more
doaj   +2 more sources

Indirect adjusted comparison of 6-month clinical outcomes between esketamine nasal spray and other real-world polypharmacy treatment strategies for treatment resistant depression: results from the ICEBERG study [PDF]

Frontiers in Psychiatry, 2023
BackgroundThe efficacy of esketamine nasal spray (NS) as a rapid-acting agent for treatment resistant depression (TRD) was demonstrated in comparisons with placebo, when both were given in addition to a newly initiated selective serotonin reuptake ...
Albino J. Oliveira-Maia, Albino J. Oliveira-Maia, Benoit Rive, Joachim Morrens, Yordan Godinov, Jedelyn Cabrieto, Nolen Perualila, Siobhán Mulhern-Haughey   +7 more
doaj   +2 more sources

Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant [PDF]

Health and Quality of Life Outcomes, 2023
Background Patients with treatment-resistant depression (TRD) report significant deficits in physical and mental health, as well as severely impaired health-related quality of life (HRQoL) and functioning.
Carol Jamieson, Vanina Popova, Ella Daly, Kimberly Cooper, Wayne C. Drevets, Heather M. Rozjabek, Jaskaran Singh   +6 more
doaj   +2 more sources

Esketamine Nasal Spray for Treatment-Resistant Bipolar II Depression: A Case Report. [PDF]

Psychiatry Investig
This case report discusses a 62-year-old male with treatment-resistant bipolar II depression and hypertension. After poor responses to multiple treatments, an add-on esketamine nasal spray (ESK-NS) was introduced in October 2022. Improvement was seen, and the patient’s depressive episode was nearly remitted during the maintenance phase.
Lin HC, Chang CY, Lin CH, Chiang YC, Chang CH.   +4 more
europepmc   +2 more sources

Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression. [PDF]

Clin Pharmacol Ther, 2021
This post hoc analysis assessed the benefit–risk profile of esketamine nasal spray + oral antidepressant (AD) induction and maintenance treatment in patients with treatment‐resistant depression (TRD). The Benefit–Risk Action Team framework was utilized to assess the benefit–risk profile using data from three induction studies and one maintenance study.
Katz EG, Hough D, Doherty T, Lane R, Singh J, Levitan B.   +5 more
europepmc   +4 more sources

Esketamine Nasal Spray: Rapid Relief for TRD and Suicide Prevention-Mechanisms and Pharmacodynamics. [PDF]

Neuropsychiatr Dis Treat
Esketamine nasal spray has emerged as a promising rapid-relief therapy for treatment-resistant depression (TRD) and suicide prevention. This review examines the chemical structure and pharmacodynamics of esketamine, highlighting its primary action on NMDA receptors and additional effects on AMPA receptors, opioid receptors, monoaminergic receptors, and
Song H, Luo Y, Fang L.
europepmc   +3 more sources

A Meta-Analysis of the Antidepressant Responses in Pivotal Trials on Esketamine Nasal Spray and Atypical Antipsychotics [PDF]

Neuropsychiatric Disease and Treatment, 2023
Lien Wang,1,2 Xiaowei Chen,1 Xiaojing Gu,1 Heidi De Smedt,3 Vanina Popova,3 Dong-Jing Fu,4 Carla M Canuso,4 Wayne C Drevets,2 Guang Chen2 1Janssen Research & Development, LLC, Janssen Pharmaceutical Companies of Johnson & Johnson, Shanghai, People’s ...
Wang L, Chen X, Gu X, De Smedt H, Popova V, Fu DJ, Canuso CM, Drevets WC, Chen G   +8 more
doaj   +2 more sources

Esketamine nasal spray compassionate use program in the Netherlands:An open label, multi-center cohort study in severe treatment-resistant depression [PDF]

Journal of Affective Disorders Reports
Background: Esketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist, used intranasally (IN), is applied as an antidepressant (AD) in treatment-resistant depressed (TRD) patients. Real-world studies with IN esketamine are still scarce.Objectives: To
Busz, K.A.J., Cath, D., de Jong, M., de Waardt, D.A., Foeken, K., Mertens, J.B.C., Olivier, E.J.F.L., Ruhe, Henricus (H G.)., Schmidt, E.J., Schruers, K.R.J., Schutters, S.I.J., Strootker, W.J., van den Brink, R.H.S., van Noorden, M.S., van Son, J., Venema, H.C.P., Zantvoord, J.B.   +16 more
core   +3 more sources

Mental Health-Related Disability Days and Costs Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray and Conventional Therapies in the USA [PDF]

Drugs - Real World Outcomes
Introduction Treatment-resistant depression (TRD) is related to disproportionate unemployment and productivity burden in the USA. The current study describes real-world mental health (MH)-related disability days and costs of patients with TRD initiated ...
Manish K. Jha, Maryia Zhdanava, Aditi Shah, Arthur Voegel, Anabelle Tardif-Samson, Dominic Pilon, Kruti Joshi   +6 more
doaj   +2 more sources

Treating Treatment-resistant Depression with Esketamine Nasal Spray When All Therapeutic Options Have Been Exhausted: Clinical Experience from a Spanish Cohort of Expanded Use. [PDF]

Clin Psychopharmacol Neurosci
Depressive disorder; Esketamine; Treatment-resistantTrastorno depresivo; Esketamina; Resistente al tratamientoTrastorn depressiu; Esketamina; Resistent al tractamentObjective: Treatment Resistant Depression (TRD) is commonly defined as the lack of ...
Vendrell-Serres J, Soto-Angona Ó, Rodríguez-Urrutia A, Inzoli B, González AL, Ramos-Quiroga JA.   +5 more
europepmc   +3 more sources